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Katalin Re´ve´sz, c Ro´bert E. Gyurcsa´nyi d and Tama´s Me´sza´ros *aeWe demonstrate the ﬁrst application of a nuclease resistant aptamer,
the so-called Spiegelmer, in a sandwich-type aﬃnity assay by quan-
titative assessment of cardiac Troponin I (cTnI) in blood serum
samples. To this end, we used a bead-based homogenous proximity
assay (AlphaLISA) in which luminescence is generated by the Spie-
gelmer and antibody-modiﬁed donor and acceptor beads brought
into proximity by their binding to cTnI.Prompt, on-site diagnosis of Acute Coronary Syndrome (ACS) is
the prerequisite for timely triage of patients with acute chest
pain. Two subunits of the cardiac troponin complex, troponin I
(cTnI) and troponin T (cTnT), are derived from genes speci-
cally expressed in the myocardium; therefore, their appearance
in the systemic circulation is a highly selective indicator of
cardiomyocyte necrosis.1,2 Presently, all clinically applied diag-
nostic devices of cardiac troponins are based on immunoassays
and thus require antibodies.3 The standardization of cTnI
immunoassays is complicated by the presence of various forms
of cTnI in circulation, i.e., monomer protein, in interaction with
cTnT (TI) and as a tertiary troponin complex that includes
additionally Troponin C (CTI). Further diﬃculties are raised by
the association of cTnI with autoantibodies and heparin, and by
posttranslational modications.4 It was reported that assays
using diﬀerent antibody pairs may reach up to 40 fold devia-
tions of measured cTnI concentration.5 This problem isecular Biology and Pathobiochemistry,
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hemistry 2017addressed by assay-specic threshold levels for each commer-
cial cTnI assay, which are not interchangeable and therefore
may lead to misinterpretations.6 Aptamer-based assays may
provide a solution for these standardization problems by
appropriate epitope targeting and counterselection to critical
interferents. Furthermore, aptamers – in contrast to antibodies
– can be produced by cost-eﬀective chemical synthesis with
orientated modications and preserve their functionality even
under harsh prevailing conditions; thus, they can outperform
antibodies in diagnostic applications.7 On the other hand, the
most generally examined specimens of human diagnostics,
blood plasma and serum, include a panel of nucleases that
might expeditiously degrade oligonucleotides severely limiting
leveraging aptamers as receptors of biomarker determining
assays.8 With these advantages and drawbacks of aptamers in
mind, we previously developed a cTnI selective Spiegelmer9 for
a specic N-terminal epitope of cTnI with a rationally designed
selection procedure. Spiegelmers10 are enantiomeric aptamers,
which are composed of L-20-deoxyribose units and thus fully
withstand enzymatic degradation. Hitherto, Spiegelmers have
been used for therapeutic purposes with promising results but
their diagnostic exploitation has not been explored yet.11 In the
present study, we attempted the analytical application of our
Spiegelmer to test whether it can substitute antibodies of
sandwich type assays for quantitative assessment of cTnI in
human serum. To implement these proof-of-principle studies,
we used a highly sensitive, bead-based homogenous proximity
assay, the so-called AlphaLISA.12 This method relies on selective
antibody coated donor and acceptor beads that are brought into
proximity through binding to the pertinent analyte. Upon light
exposure, the donor bead released singlet oxygen reaches the
acceptor beads in vicinity and produces a luminescence
signal.13 Here, we used streptavidin donor and protein A
acceptor beads of AlphaLISA, which could be conveniently
modied using a biotin tagged Spiegelmer and a cTnI selective
antibody, respectively (Fig. 1).
Since our previously generated Spiegelmer was directed
against an N terminal peptide sequence of cTnI, we choseAnal. Methods, 2017, 9, 5091–5093 | 5091
Fig. 1 Schematics of the Spiegelmer-antibody assay. The Spiegelmer
coated donor and the antibody coated acceptor beads are brought
into proximity in the presence of cTnI. The donor bead produced
singlet oxygen travels to the acceptor bead and induces
chemiluminescence.
Fig. 2 AlphaLISA signal as a function of concentration of cTnI. The
diluted serum was formulated with of an ITC complex chosen by the
AACC cTnI Standardization Subcommittee as the international refer-
ence material. The adjusted R-square value was 0.994.
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View Article Onlinea commercial antibody that was raised against a C terminal
epitope of our protein of interest to avoid the rivalry of the two
receptors for the same binding site. To study the potential
clinical impact of the selected Spiegelmer, experiments were
implemented in serum, a general specimen of ACS diagnosis.
Blood serum is one of the most complex proteomes of diag-
nostics and the concentrations of its protein components vary
by up to 10 orders of magnitude. Besides albumin, various
antibodies of mmolar range concentrations are the most prev-
alent proteins of serum.14 In order to attain the optimal signal
intensity of AlphaLISA, the protein A acceptor bead has to be
incubated with a cTnI selective antibody at low nanomolar
concentration. Consequently, the cTnI selective antibody is
replaced on the protein A acceptor bead upon addition of serum
with inherently high antibody concentration. To overcome this
shortcoming, a cTnI selective antibody was covalently linked to
the protein A bead by using the dimethyl pimelimidate cross-
linking agent prior to its addition to the blood serum. The
labelled Spiegelmer and streptavidin donor bead could be
infused into the serum without any pretreatment, due to the
extraordinarily selective and strong interaction of streptavidin
and biotin.
Myocardial injury results in the release of cTnI in various
forms. In order to assess the applicability of our Spiegelmer as
a synthetic cTnI receptor of sandwich assays, diluted, troponin-
free serum was spiked with various amounts of CTI, the gener-
ally accepted reference material of cTnI measurment. It is well
documented that cTnI is prone to degradation and binding to
plastic and glass surfaces.15,16 Therefore, the dilution linearity was
analysed by determining the cTnI concentration of spiked spec-
imens with a clinically applied, two-step chemiluminescence
immunoassay, which is distributed by ARCHITECT under the
brand name STAT Troponin-I. In the rst step, cTnI binds to
antibody-coated paramagnetic microparticles. Following separa-
tion and washing of the beads, an anti-troponin-I acridinium-
labeled conjugate is added in the second step. Aer washing
and addition of enhancer solutions, the chemiluminescence
reaction produced signal is measured. The obtained data illus-
trated the problems of cTnI standardization. The measured cTnI
concentrations of CTI spiked samples were app. two times lower
than the calculated ones (ESI Table 1†).
Next, the samples were studied by using AlphaLISA. To this
end, a protein A acceptor bead-coupled cTnI selective antibody5092 | Anal. Methods, 2017, 9, 5091–5093and biotin labelled Spiegelmer were added to the dilution series
and the mixture was incubated for 1 h. In the following step, the
mixture was completed with streptavidin donor beads and
incubated for a further hour and then the luminescence signals
were measured. The obtained data demonstrated low standard
deviation of the parallel samples and the plotted luminescence
signal intensity showed good linearity in the ng ml1 range of
troponin (Fig. 2).
These results suggest that the Spiegelmer is suitable for cTnI
measurement in diluted serum but did not provide information
about the specicity of the developed assay. To study whether
our AlphaLISA could discriminate the skeletal muscle and car-
diomyocyte isoform of troponin I, a cross-reactivity study was
implemented by spiking the serum with troponin-free 50 ng
ml1 nal assay concentration of sTnI and conducting the
AlphaLISA measurement as described above. The produced
luminescence signal remained at the level of those detected
with cTnI-free serum samples implying high specicity of the
Spiegelmer-based sandwich assay (Fig. 2).
The optimal cTnI level monitoring assay is expected to detect
the various forms of the protein; therefore, it was also studied if
the developed AlphaLISA is capable of measuring the concen-
tration of the cTnI monomer. It was described that the cTnI
monomer was even more prone to degradation than the CTI
complex.17 Therefore, the actual concentration of the recombi-
nant cTnI supplemented serum samples were also determined
by STAT Troponin-I measurement. According to the obtained
data, the calculated concentration was app. 20 times higher
than the determined one (ESI Table 2†) again indicating the
challenges of cTnI measurement. Having determined the
concentration of cTnI spiked samples, the AlphaLISA produced
luminescence was detected following the previously applied
protocol. The intensity of the luminescence signal correlated
well with the amount of the added cTnI indicating that theThis journal is © The Royal Society of Chemistry 2017
Fig. 3 AlphaLISA signal as a function of the concentration of cTnI. The
diluted serum was formulated with recombinant cTnI. The adjusted R-
square value of the linear response was 0.985.
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View Article OnlineSpiegelmer-antibody sandwich assay is capable for monitoring
the cTnI monomer too (Fig. 3).Conclusions
Presently, most of the diagnostic devices adopt antibodies for
selective detection of biomarker proteins. Despite some
essential advantages over antibodies, leveraging of aptamers
for diagnostics is still awaited. The presented proof-of-
principle study shows the rst example of using a fully
nuclease resistant aptamer, the so-called Spiegelmer, for the
development of a cTnI detecting sandwich assay. The obtained
results demonstrate that the Spiegelmer can ensure the
required selectivity and can detect various forms of cTnI in
serum at physiologically relevant low pM concentrations.
Although its LOD is much higher than those of the presently
available high sensitivity cTnI measuring kits,18 the developed
protocol shows applicability of Spiegelmers as receptors of
sandwich assays for biomarker analysis of blood serum. The
most important features of diagnostic receptors are the
selectivity and the KD value of receptor and target protein
complexes, since smaller the KD the lower the expected LOD is.
An extended analysis has revealed that the monoclonal anti-
bodies of high sensitivity cTnI diagnostic kits possess KD
values in the 74 nM to 2.6 mM range, which are at least an order
of magnitude higher than that of our Spiegelmer (3.5 nM).9
Therefore, it is expected that further assay optimization or
usage of more sensitive detection approaches would make
achievable the desired LOD of cTnI assays by employing
Spiegelmers. Notwithstanding, the presented results signify
the applicability of Spiegelmers as diagnostic receptors;
hence, they could pave the way for the development of
oligonucleotide-based, biomarker detecting devices.This journal is © The Royal Society of Chemistry 2017Acknowledgements
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